[시장보고서]세계의 제12인자 억제제 시장 보고서(2025년)

세계의 제12인자 억제제 시장 보고서(2025년)

Factor XII Inhibitors Global Market Report 2025

상품코드 : 1889381

리서치사 : The Business Research Company

발행일 : On Demand Report

페이지 정보 : 영문 250 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,490

￦ 6,573,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490

￦ 9,501,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490

￦ 12,429,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

제12인자 억제제 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 12억 6,000만 달러에서 2025년에는 14억 달러로, CAGR 11.3%로 성장하였습니다. 지난 수년간의 성장은 혈전증의 유병률 증가, 보다 안전한 항응고제에 대한 수요 증가, 임상 검사 활동의 지속적인 확대, 접촉 채널에 의한 치료법의 인지도 향상, 제12인자 억제의 치료적 잠재성에 대한 인식의 확산으로 인한 것으로 예측됩니다.

제12인자 억제제 시장 규모는 향후 수년간 급속한 성장이 예상됩니다. 2029년에는 21억 2,000만 달러에 달하고, CAGR은 10.9%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 혈전성 질환과 심혈관 질환의 증례 증가, 보다 안전한 항응고제에 대한 수요 증가, 유전성 혈관성 부종의 치료 선택에 대한 인지도 향상, 제12인자 억제제를 평가하는 임상 검사 증가, 생물제제와 단일클론항체의 사용 확대 등이 있습니다. 예측기간 동안 예상되는 주요 동향으로는 항응고제 설계의 기술적 진보, 표적 식별용 인공지능(AI)의 활용, 보다 안전한 항응고기전으로의 이행, 생명공학기업과 제약기업 간의 전략적 제휴, 외과 수술기술의 진보 등이 있습니다.

혈전성 질환의 발생률 상승이 제12인자 억제제 시장의 성장을 이끌 것으로 예측됩니다. 정맥 혈전과 동맥 혈전을 포함한 혈전성 질환은 혈류를 억제하고 심각한 건강 합병증을 유발할 수 있습니다. 비활동적인 생활 습관이 혈류 저해 및 응고 위험 상승에 기여하고 있기 때문에 혈전성 질환의 발생률은 증가세에 있습니다. 제12인자 억제제는 정상적인 지혈 기능을 방해하지 않고 접촉 활성화 채널을 선택적으로 억제함으로써 비정상적인 혈전 형성을 예방합니다. 이 목표 지향 접근법은 출혈 위험을 줄이면서 효과적인 혈전증 관리를 가능하게 합니다. 예를 들어, 2025년 1월에 미국 질병 예방관리센터(CDC)가 보고한 바에 따르면 연간 약 90만명의 미국인이 정맥혈전색전증의 영향을 받고 있으며, 6만-10만명이 사망하는 것으로 추정되고 수많은 장기적인 합병증이 발생하고 있습니다. 따라서, 혈전성 질환의 유병률의 상승이 제12인자 억제제 수요를 견인하고 있습니다.

표적 요법에 대한 관심 증가는 제12인자 억제제 시장을 더욱 촉진하고 있습니다. 표적 요법은 질병의 분자 이상을 정밀하게 억제하고 건강한 조직에 대한 손상을 줄여 치료 성과를 향상시킵니다. 환자의 유전자 프로파일에 치료를 적응시키는 정밀의료의 진보가 이러한 요법의 도입을 가속화하고 있습니다. 제12인자 억제제는 내인성 응고 채널을 선택적으로 조절하여 표적 요법을 보완하고 기존 항응고제에 비해 출혈 위험을 최소화하여 치료 안전성을 높입니다. 예를 들어, 2024년 12월에 미국 유전자 세포 치료 학회(ASGCT)가 보고한 바에 의하면, FDA는 2023년에 6개의 유전자 치료 제품을 승인하였으며, 이는 2022년의 5개 제품에서 증가하여 정밀의료의 중시가 고조되는 추세를 반영하고 있습니다.

세계의 제12인자 억제제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 제12인자 억제제 시장 : 성장률 분석
세계의 제12인자 억제제 시장 실적 : 규모와 성장(2019-2024년)
세계의 제12인자 억제제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 제12인자 억제제 : 총 시장 규모(TAM)

제6장 시장 세분화

세계의 제12인자 억제제 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체
저분자 억제제
기타
세계의 제12인자 억제제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
주사
기타
세계의 제12인자 억제제 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
유전성 혈관성 부종
혈전증
염증성 질환
기타
세계의 제12인자 억제제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
연구기관
기타
세계의 제12인자 억제제 시장 : 단일클론항체별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
완전 인간 단일클론항체
인간화 단일클론항체
키메라 단일클론항체
이중특이 단일클론항체
단일 체인 가변 도메인 단편(scFv) 항체
세계의 제12인자 억제제 시장 : 저분자 억제제별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
직접적 제12인자 억제제
알로스테릭 제12인자 억제제
가역적 억제제
비가역적 억제제
펩티드 모방 억제제
세계의 제12인자 억제제 시장 : 기타별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
펩티드계 억제제
RNA 간섭(RNAi) 치료
안티센스 올리고뉴클레오타이드
병용 요법

제7장 지역별 및 국가별 분석

세계의 제12인자 억제제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 제12인자 억제제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제12인자 억제제 시장 : 경쟁 구도
제12인자 억제제 시장 : 기업 프로파일
- Taylor & Francis Group
- Santa Cruz BIoTechnology Inc.
- CSL Limited
- Bridge Medicines Inc.
- KalVista Pharmaceuticals Inc.

제31장 기타 주요 기업 및 혁신 기업

Ovid Technologies Inc.
Affinity Biologicals Inc.
Lunac Therapeutics Ltd.
Grantome LLC

제32장 세계 시장의 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

제12인자 억제제 시장(2029년) : 새로운 기회를 제공하는 국가
제12인자 억제제 시장(2029년) : 새로운 기회를 제공하는 부문
제12인자 억제제 시장(2029년) : 성장 전략
- 시장 동향에 의한 전략
- 경쟁 전략

제36장 부록

CSM

영문 목차

영문목차

Factor XII inhibitors are therapeutic agents that block the activity of coagulation Factor XII, a protein responsible for initiating the intrinsic blood-clotting pathway. They inhibit downstream clotting processes without significantly disrupting normal hemostasis. Their primary purpose is to reduce abnormal thrombosis and other clot-related conditions while offering a lower bleeding risk than traditional anticoagulants.

The key drug types of Factor XII inhibitors include monoclonal antibodies, small-molecule inhibitors, and others. Monoclonal antibodies are laboratory-produced antibodies that specifically target and inhibit Factor XII to prevent abnormal clot formation with minimal bleeding risk. These therapies are delivered through oral, injectable, or other administration routes. They are used for conditions such as hereditary angioedema, thrombosis, inflammatory disorders, and more, serving end users including hospitals, specialty clinics, research institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The factor XII inhibitors market research report is one of a series of new reports from The Business Research Company that provides factor XII inhibitors market statistics, including factor XII inhibitors industry global market size, regional shares, competitors with a factor XII inhibitors market share, detailed factor XII inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the factor XII inhibitors industry. This factor XII inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The factor XII inhibitors market size has grown rapidly in recent years. It will grow from $1.26 billion in 2024 to $1.40 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. Growth in the historic period can be attributed to the increasing prevalence of thrombosis, a rising need for safer anticoagulants, continued growth in clinical trial activity, greater awareness of contact pathway-based therapies, and expanding recognition of the therapeutic potential of Factor XII inhibition.

The factor XII inhibitors market size is expected to see rapid growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. Growth in the forecast period can be linked to rising cases of thrombotic and cardiovascular diseases, increasing demand for safer anticoagulant medications, growing awareness of hereditary angioedema treatment options, an uptick in clinical trials evaluating FXII inhibitors, and the expanding use of biologics and monoclonal antibodies. Major trends expected in the forecast period include technological progress in anticoagulant drug design, the use of artificial intelligence for target identification, a shift toward safer anticoagulant mechanisms, strategic partnerships between biotechnology companies and pharmaceutical firms, and advancements in surgical techniques.

The rising incidence of thrombotic disorders is expected to drive the growth of the Factor XII inhibitors market. Thrombotic disorders, including venous and arterial blood clots, can block circulation and lead to serious health complications. Their incidence is increasing due to sedentary lifestyles, which contribute to poor blood flow and higher clotting risk. Factor XII inhibitors help prevent abnormal clot formation by selectively blocking the contact activation pathway without interfering with normal hemostasis. This targeted approach allows effective thrombosis management while lowering bleeding risk. For example, in January 2025, the Centers for Disease Control and Prevention (CDC) reported that approximately 900,000 Americans are affected by venous thromboembolism annually, with an estimated 60,000-100,000 deaths and numerous long-term complications. Therefore, the rising prevalence of thrombotic disorders is driving demand for Factor XII inhibitors.

The increasing focus on targeted therapies is further propelling the Factor XII inhibitors market. Targeted therapies precisely inhibit molecular abnormalities in diseases, reducing harm to healthy tissues and improving treatment outcomes. Advances in precision medicine, which tailor treatments to patients' genetic profiles, have accelerated the adoption of such therapies. Factor XII inhibitors complement targeted therapies by selectively modulating the intrinsic coagulation pathway, minimizing bleeding risks compared to conventional anticoagulants and enhancing treatment safety. For instance, in December 2024, the American Society of Gene & Cell Therapy (ASGCT) reported that the FDA approved six gene therapy products in 2023, up from five in 2022, reflecting the growing emphasis on precision medicine.

Key companies in the Factor XII inhibitors market are developing innovative therapies, such as anti-FXIIa monoclonal antibodies, to improve treatment efficacy and patient outcomes. Anti-FXIIa monoclonal antibodies specifically inhibit activated Factor XII to prevent abnormal clot formation while preserving normal hemostasis. For example, in February 2025, CSL Behring GmbH, a Germany-based biopharmaceutical company, received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) 200 mg subcutaneous injection pens. ANDEMBRY is a human anti-activated Factor XII monoclonal antibody approved for preventing acute attacks of hereditary angioedema (HAE), acting on Factor XIIa, a key trigger of HAE episodes, and is conveniently administered via subcutaneous injection.

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

North America was the largest region in the factor XII inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in factor XII inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the factor XII inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The factor XII inhibitors market consists of revenues earned by entities by providing services such as formulation development, drug delivery optimization, laboratory testing, diagnostic support, regulatory consulting, pharmacovigilance, and contract manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The factor XII inhibitors market also includes sales of anticoagulant formulations, combination therapies, diagnostic kits, research reagents, laboratory consumables, and supportive medical devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Factor XII Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on factor xii inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for factor xii inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The factor xii inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Monoclonal Antibodies; Small Molecule Inhibitors; Other Drug Types
2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
3) By Application: Hereditary Angioedema; Thrombosis; Inflammatory Disorders; Other Applications
4) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors
3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies
Companies Mentioned: Taylor & Francis Group; Santa Cruz Biotechnology Inc.; CSL Limited; Bridge Medicines Inc.; KalVista Pharmaceuticals Inc.; Ovid Technologies Inc.; Affinity Biologicals Inc.; Lunac Therapeutics Ltd.; Grantome LLC
Countries:

1. Executive Summary

2. Factor XII Inhibitors Market Characteristics

3. Factor XII Inhibitors Market Trends And Strategies

4. Factor XII Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Factor XII Inhibitors Growth Analysis And Strategic Analysis Framework

5.1. Global Factor XII Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Factor XII Inhibitors Market Growth Rate Analysis
5.4. Global Factor XII Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Factor XII Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Factor XII Inhibitors Total Addressable Market (TAM)

6. Factor XII Inhibitors Market Segmentation

6.1. Global Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Small Molecule Inhibitors
Other Drug Types
6.2. Global Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Other Routes Of Administration
6.3. Global Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hereditary Angioedema
Thrombosis
Inflammatory Disorders
Other Applications
6.4. Global Factor XII Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Research Institutes
Other End-Users
6.5. Global Factor XII Inhibitors Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fully Human Monoclonal Antibodies
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Bispecific Monoclonal Antibodies
Single-Chain Variable Fragment (scFv) Antibodies
6.6. Global Factor XII Inhibitors Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct Factor XII Inhibitors
Allosteric Factor XII Inhibitors
Reversible Inhibitors
Irreversible Inhibitors
Peptidomimetic Inhibitors
6.7. Global Factor XII Inhibitors Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peptide-Based Inhibitors
Peptide-Based Inhibitors
RNA Interference (RNAi) Therapeutics
Antisense Oligonucleotides
Combination Therapies

7. Factor XII Inhibitors Market Regional And Country Analysis

7.1. Global Factor XII Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Factor XII Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Factor XII Inhibitors Market

8.1. Asia-Pacific Factor XII Inhibitors Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Factor XII Inhibitors Market

9.1. China Factor XII Inhibitors Market Overview
9.2. China Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Factor XII Inhibitors Market

10.1. India Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Factor XII Inhibitors Market

11.1. Japan Factor XII Inhibitors Market Overview
11.2. Japan Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Factor XII Inhibitors Market

12.1. Australia Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Factor XII Inhibitors Market

13.1. Indonesia Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Factor XII Inhibitors Market

14.1. South Korea Factor XII Inhibitors Market Overview
14.2. South Korea Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Factor XII Inhibitors Market

15.1. Western Europe Factor XII Inhibitors Market Overview
15.2. Western Europe Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Factor XII Inhibitors Market

16.1. UK Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Factor XII Inhibitors Market

17.1. Germany Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Factor XII Inhibitors Market

18.1. France Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Factor XII Inhibitors Market

19.1. Italy Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Factor XII Inhibitors Market

20.1. Spain Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Factor XII Inhibitors Market

21.1. Eastern Europe Factor XII Inhibitors Market Overview
21.2. Eastern Europe Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Factor XII Inhibitors Market

22.1. Russia Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Factor XII Inhibitors Market

23.1. North America Factor XII Inhibitors Market Overview
23.2. North America Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Factor XII Inhibitors Market

24.1. USA Factor XII Inhibitors Market Overview
24.2. USA Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Factor XII Inhibitors Market

25.1. Canada Factor XII Inhibitors Market Overview
25.2. Canada Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Factor XII Inhibitors Market

26.1. South America Factor XII Inhibitors Market Overview
26.2. South America Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Factor XII Inhibitors Market

27.1. Brazil Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Factor XII Inhibitors Market

28.1. Middle East Factor XII Inhibitors Market Overview
28.2. Middle East Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Factor XII Inhibitors Market

29.1. Africa Factor XII Inhibitors Market Overview
29.2. Africa Factor XII Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Factor XII Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Factor XII Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Factor XII Inhibitors Market Competitive Landscape And Company Profiles

30.1. Factor XII Inhibitors Market Competitive Landscape
30.2. Factor XII Inhibitors Market Company Profiles
- 30.2.1. Taylor & Francis Group Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Santa Cruz Biotechnology Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. CSL Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bridge Medicines Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. KalVista Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Factor XII Inhibitors Market Other Major And Innovative Companies

31.1. Ovid Technologies Inc.
31.2. Affinity Biologicals Inc.
31.3. Lunac Therapeutics Ltd.
31.4. Grantome LLC

32. Global Factor XII Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Factor XII Inhibitors Market

34. Recent Developments In The Factor XII Inhibitors Market

35. Factor XII Inhibitors Market High Potential Countries, Segments and Strategies

35.1 Factor XII Inhibitors Market In 2029 - Countries Offering Most New Opportunities
35.2 Factor XII Inhibitors Market In 2029 - Segments Offering Most New Opportunities
35.3 Factor XII Inhibitors Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer